Ipamorelin
Selective Growth Hormone Secretagogue Receptor Agonism
What is Ipamorelin?
Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Rather than acting on the GHRH receptor, it functions as an agonist at the growth hormone secretagogue receptor (GHS-R1a) — the same receptor targeted by the endogenous hormone ghrelin. When it binds this receptor on pituitary and hypothalamic cells, preclinical studies show it triggers the release of stored growth hormone (GH). Because it mimics ghrelin's signaling at the receptor level, it is sometimes described as a 'ghrelin mimetic,' although it was specifically designed to be more selective than earlier compounds in its class.
What distinguishes ipamorelin in the research literature is that selectivity. Earlier GH secretagogues such as GHRP-6 tended to also stimulate the release of cortisol and prolactin and to provoke hunger through broader receptor activity. Preclinical work suggests ipamorelin releases GH with comparatively little effect on cortisol or prolactin, which is why it is often characterized as one of the 'cleaner' secretagogues studied. Like GHRH analogs, it is thought to work with the body's pulsatile secretion pattern rather than overriding it, and downstream elevations in insulin-like growth factor 1 (IGF-1) are described in animal models. Ipamorelin and the GHRH analog CJC-1295 are frequently paired in research because they act on two different receptor systems, and studies suggest that combining a GHRH signal with a ghrelin-receptor signal can produce a larger, synergistic GH pulse than either alone.
As with other secretagogues, the human evidence base is limited. Much of the characterization comes from animal and in-vitro studies and early-phase pharmacology, and claims about muscle growth, fat loss, recovery, or sleep in humans remain largely unproven in controlled trials. Ipamorelin is not approved for human use by major regulatory authorities. This information is presented strictly for research and educational purposes only.
Molecular data
Mechanism of action
In preclinical research, Ipamorelin is associated with the following pathways and targets:
Research highlights
- Selective GHS-R1a agonism with minimal off-target receptor activity
- Stimulates GH release without significant cortisol elevation
- Synergistic with CJC-1295 for amplified GH pulse amplitude
- Well-characterized safety profile in preclinical studies
Frequently asked questions
What is Ipamorelin in research?
Ipamorelin is a synthetic pentapeptide studied as a selective growth hormone secretagogue. In preclinical models it acts as an agonist at the ghrelin receptor (GHS-R1a) and stimulates the pituitary to release growth hormone, making it a tool for investigating GH secretion pathways.
How is Ipamorelin different from CJC-1295?
They target different receptors. CJC-1295 is a GHRH analog that acts on the GHRH receptor, while ipamorelin acts on the ghrelin/GHS-R receptor. Both increase growth hormone release in studies, but through distinct mechanisms, which is why researchers often examine them together rather than as interchangeable compounds.
Why is Ipamorelin called a selective GH secretagogue?
Earlier secretagogues such as GHRP-6 tended to also raise cortisol and prolactin and stimulate appetite. Preclinical research suggests ipamorelin promotes growth hormone release with comparatively little effect on those other hormones, so it is often described as more selective or 'cleaner.' This characterization comes mainly from animal and in-vitro data.
How do CJC-1295 and Ipamorelin work together in studies?
Because CJC-1295 activates the GHRH receptor and ipamorelin activates the ghrelin receptor, combining them engages two separate signaling systems at once. Research suggests this can produce a larger, synergistic growth hormone pulse than either alone. These are laboratory findings and not validated human dosing protocols.
Does Ipamorelin raise cortisol?
Preclinical studies suggest ipamorelin stimulates growth hormone release with minimal impact on cortisol or prolactin, which is a key reason it is described as selective. However, this is based largely on animal and early-phase data, and its full profile in humans is not established through large controlled trials.
Source Ipamorelin at Purgo Labs
≥99% purity, third-party COA verification, and same-day fulfillment.
Shop Ipamorelin at Purgo Labs ↗Related compounds
For research and educational purposes only. Ipamorelin is not approved for human use by any regulatory authority, and nothing on this page constitutes medical advice, diagnosis, or treatment. Research findings referenced here are predominantly preclinical.